

19th MEET THE PROFESSOR

Advanced International Breast Cancer Course (AIBCC)

PADOVA,
SEPTEMBER 21st-22nd, 2023

www.accmed.org



GYMNASIVM
MNIVM DISCIPLINA

PRINCIPE PASCHALI CICONIA
PRAESIDI JOANNE SVPERANTIO EQ. ET FEDERICO
REFORMATORIBVS IO. FRANC. PRIOLO DOCTORE, ZACHA
LEONARDO DONATO EQ. INSTAVRATVM ANNO M



Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 19th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

Educational material

The event educational material can be downloaded starting October 5th on askit.accmed.org

Programme

Thursday, September 21st

10.00 **Introduction to the Conference**
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly

10.30 **Gene expression tools in early-stage HR+/HER2- breast cancer: when and which one?**
Gaia Griguolo

11.00 **Biological insights of the immune system in breast cancer**
Maria Vittoria Dieci

11.30 **DNA NGS-based biomarkers in advanced breast cancer: how, where and which ones?**
Mafalda Oliveira

12.00 **Tackling diversity in HER2-positive breast cancer: biological and clinical implications**
Tomás Pascual

12.30 **Discussion**

13.00 *Lunch*

SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS

The changing relationship between locoregional recurrences and long-term outcomes

Chairpersons: Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas

14.00 **Mapping local and regional recurrences**
Orit Kaidar-Person

14.30 **The surgical perspective**
Eleftherios Mamounas

15.00 **Deciphering the EBCTCG meta-analyses**
Philip Poortmans

15.30 **Discussion**

Multidisciplinary Tumor Board 1 – Locoregional treatment

Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Hesham Ahmed Gaballah Elghazaly

- 16.00 **Clinical case 1. Skin flap thickness for IBR** – Rosa Di Micco
- 16.15 **Clinical case 2. When to resect/irradiate after systemic therapy for a recurrence** – Luca Visani
- 16.30 **Clinical case 3. Local recurrence after DCIS** – Eleonora Ferrara
- 16.45 **General discussion and concluding comments:** Jacek Jassem, Hesham Ahmed Gaballah Elghazaly
- 17.00 **Adjourn**

- 17.15 **Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2023**
- 17.30 **Lecture of the Awardee**
- 18.00 **Adjourn and cocktail**

Friday, September 22nd

SESSION III – EARLY BREAST CANCER

Chairpersons: Alessandra Gennari, Valentina Guarneri

- 9.00 **New therapeutic strategies in very young women: lights and shadows**
Angela Toss
- 9.20 **Elderly patients: how old is too old in the contemporary scenario**
Laura Biganzoli
- 9.40 **Neoadjuvant approach: rethinking the paradigm?**
Federica Miglietta
- 10.00 **New ESMO Guidelines**
Valentina Guarneri
- 10.20 **Discussion**
- 10.50 *Coffee break*

Multidisciplinary Tumor Board 2 - Early breast cancer

Panelists: Maria Vittoria Dieci, Alessandra Gennari, Valentina Guarneri, Eleftherios Mamounas, Philip Poortmans

11.15 Clinical case 1. Genomic test in premenopausal patients

Davide Massa

11.30 Clinical case 2. Adjuvant CDK 4/6 in patients with potential clinical indication but with low genomic risk-

Michele Bottosso

11.45 Clinical case 3. HER2+ pt1cN0: adjuvant or neoadjuvant?

Ottavia Amato

12.00 General discussion and concluding comments: Alessandra Gennari

12.30 *Lunch*

SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS

Chairpersons: Giuseppe Curigliano, Pierfranco Conte

13.30 HR+ disease: is there any preferred treatment sequence at the time of endocrine-resistance?

Stephen Johnston

14.00 HER2+ disease: from guidelines to a personalized approach based on tumor and patient characteristics

Sandra Swain

14.30 Triple negative disease: something more than label indications to dictate treatment sequence?

Hope Rugo

15.00 Discussion

Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer

Panelists: Pierfranco Conte, Giuseppe Curigliano, Stephen Johnston, Hope Rugo, Sandra Swain

15.30 Clinical case 1. Visceral crisis – Grazia Vernaci

15.45 Clinical case 2. Oligometastatic disease – Cristina Falci

16.00 Clinical case 3. Leptomeningeal metastases – Carlo Alberto Giorgi

16.15 General discussion and concluding comments: Hope Rugo

16.30 Take home messages and adjourn

Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

Honorary President

Gabriel N. Hortobagyi

*Department of Breast Medical Oncology
The University of Texas – MD Anderson Cancer Center
Houston (USA)*

Directors

Pierfranco Conte

*Coordinator Molecular Tumor Board, Rete
Oncologica Veneta, Padova (I)
Scientific Director S. Camillo Hospital, IRCCS,
Venezia (I)*

Valentina Guarneri

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Philip Poortmans

*Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Network
University of Antwerp
Wilrijk-Antwerp (B)*

Aleix Prat

*Medical Oncology Department
Hospital Clinic
Barcelona (E)*

Scientific Committee

Bettina Borisch

*Institute of Global Health
University of Geneva*

Maria Vittoria Dieci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)*

Hesham Ahmed Gaballah Elghazaly

*Department of Clinical Oncology and nuclear
medicine
University of Ainshams
Cairo (EG)*

Jacek Jassem

*Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)*

Stephen Johnston

*NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust &
Institute of Cancer Research
London (UK)*

Sibylle Loibl

*German Breast Group
University of Frankfurt (D)*

Eleftherios Mamounas

*Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (USA)*

Miguel Martin

*Medical Oncology Service
Hospital Universitario Gregorio Marañón
Madrid (E)*

Fedro Alessandro Peccatori

*Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (I)*

Sandra Swain M.

*Research Development
Georgetown University Medical Center
Washington (USA)*

Speakers & Chairpersons

Ottavia Amato

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Laura Biganzoli

*Breast Unit
Ospedale S. Stefano
Prato (I)*

Michele Bottoso

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Giuseppe Curigliano

*Department of Oncology
European Institute of Oncology
University of Milano (I)*

Rosa Di Micco

*Breast Unit
IRCCS S. Raffaele Hospital
Milano (I)*

Cristina Falci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Eleonora Ferrara

*Division of Radiotherapy
Ospedale Maggiore della Carità
UPO – University of Piemonte Orientale
Novara (I)*

Alessandra Gennari

*Division of Oncology
Ospedale Maggiore della Carità
UPO – University of Piemonte Orientale
Novara (I)*

Oreste Davide Gentilini

*Breast Unit
IRCCS S. Raffaele Hospital
Milano (I)*

Carlo Alberto Giorgi

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Gaia Griguolo

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Orit Kaidar-Person

*Breast Cancer Radiation Therapy Unit
Sheba Medical Center
Ramat Gan (IL)*

Davide Massa

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Federica Miglietta

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Mafalda Oliveira

*Medical Department of the Vall d'Hebron
University
Hospital and Vall d'Hebron Institute
of Oncology (VHIO)
Barcelona (E)*

Tomàs Pascual

*SOLTI Breast Cancer Research Group,
Barcelona, Spain
Department of Medical Oncology,
Hospital Clínic
Barcelona (E)*

Hope Rugo

*Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)*

Angela Toss

*Oncology Unit
AOU
Modena (I)*

Grazia Vernaci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Luca Visani

*Radiotherapy Unit
AOU Careggi
Firenze (I)*

Award & Fellowships

UNIVERSITY OF PADOVA AWARD FOR ADVANCES IN BREAST CANCER 2023

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The Scientific Committee will select the final winner which will be invited to present his/her study during the annual Conference.

FELLOWSHIPS

Some fellowship (for under 40) will be awarded including registration and 2 Hotel nights. Those interested should send a short CV and a motivation letter within September 7th to info.bologna@accmed.org. The organizing secretariat will confirm the award of the fellowship within September 10th and proceed with the organization of logistics.

UNDER 40

Accademia will provide a limited amount of free registrations for Physicians, Biologists, Pharmacists and Nurses "Under 40". Those interested should send email within September 7th to info.bologna@accmed.org. The organizing secretariat will confirm the registration by email.



CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (**31-385143**): **8,4 CME points**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

To obtain CME credits, participants must meet the following requirements:

1. Their declared profession/specialization must correspond to those accredited for CME.
2. They must attend at least 90% of the course.
3. They must complete the online meeting evaluation form.
4. They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.

The learning assessment test and meeting evaluation form must be submitted within three days of the event.

Registration

Online registration at <https://fad.accmad.org/course/info.php?id=1225> before **September 16th** ; the application will be completed only after the payment of the registration fee:

- **€ 120,00** for Physicians
- **€ 80,00** for graduate students

CANCELLATION AND REFUNDS

- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

Meeting Venue

Palazzo della Salute
Via San Francesco, 90
Padova

How to reach the venue:

The Center is located in the ZTL area.
We recommend the Interparking Italia – Via Trieste 50

Supported by unrestricted educational grants from

SILVER SPONSOR



BRONZE SPONSOR



CONTRIBUTORS



With the patronage of

INSTITUTIONS




PATROCINIO
REGIONE DEL VENETO



Comune di Padova



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



Rete Oncologica Veneta
Ricerca, innovazione, assistenza



Coordinamento Regionale per le
Attività Oncologiche (CRAO)



SCIENTIFIC SOCIETIES



CIPOMO

Collegio Italiano dei Primari Oncologi
Medici Ospedalieri





GYMNASIVM
NIVM DISCIPLINARVM

PRINCIPE PASCHALI GICONIA
IOANNE SVPERANTIO EQ. ET FEDERICO SAN
IBVS IO. FRANG. PRIOLO DOCTORE, ZACHARI
O DONATO EQ. INSTAVRATVM ANNO M. T

Organizer

ACCADEMIA NAZIONALE DI MEDICINA

General Manager: Stefania Ledda
Via Martin Piaggio, 17/6
16122 Genova



Information:

<http://meettheprofessor.accmed.org>
Ph. 0039 051 3780773 – mob. 370 3179858
info.bologna@accmed.org

Logistics and Technological Services

Forum Service
Via Martin Piaggio, 17/7
16122 Genova